{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:44:57Z","timestamp":1790779497827,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Granada CEI-Biotic projects"},{"name":"Ministry of Economy and competitiveness, Instituto de Salud Carlos III, Madrid"},{"name":"Feder Funds for Regional Development from the European Union"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.phrs.2018.11.039","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:53:00Z","timestamp":1543499580000},"page":"375-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["A nanodelivered Vorinostat derivative is a promising oral compound for the treatment of visceral leishmaniasis"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-6486","authenticated-orcid":false,"given":"Victoriano","family":"Corpas-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7868-7231","authenticated-orcid":false,"given":"M\u00f3nica","family":"D\u00edaz-Gavil\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Franco-Montalb\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Merino-Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"L\u00f3pez-Viota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"L\u00f3pez-Viota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9327-6182","authenticated-orcid":false,"given":"Efres","family":"Belmonte-Reche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"P\u00e9rez-del Palacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"de Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"G\u00f3mez-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Morillas-M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3981-9227","authenticated-orcid":false,"given":"Joaquina","family":"Mart\u00edn-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2018.11.039_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","article-title":"Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it?","volume":"2","author":"Freitas-Junior","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.phrs.2018.11.039_bib0010","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance","volume":"56","author":"Rijal","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2018.11.039_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.exppara.2013.07.008","article-title":"Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL\/6 mice","volume":"135","author":"de Carvalho","year":"2013","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.phrs.2018.11.039_bib0020","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.bcp.2012.06.014","article-title":"Development and therapeutic impact of HDAC6-selective inhibitors","volume":"84","author":"Dallavalle","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2018.11.039_bib0025","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1021\/acs.jmedchem.6b01595","article-title":"Lysine deacetylase inhibitors in parasites: past, present, and future perspectives","volume":"60","author":"Hailu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.039_bib0030","doi-asserted-by":"crossref","first-page":"e0004026","DOI":"10.1371\/journal.pntd.0004026","article-title":"Targeting lysine deacetylases (KDACs) in Parasites","volume":"9","author":"Wang","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.phrs.2018.11.039_bib0035","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1016\/j.bmc.2014.12.066","article-title":"Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT)","volume":"23","author":"Carrillo","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.039_bib0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.molbiopara.2006.11.011","article-title":"Analysis of the Leishmania donovani transcriptome reveals an ordered progression of transient and permanent changes in gene expression during differentiation","volume":"152","author":"Saxena","year":"2007","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.phrs.2018.11.039_bib0045","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1016\/j.bmcl.2014.08.060","article-title":"Bioorganic & Medicinal Chemistry Letters the antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors","volume":"24","author":"Sodji","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2018.11.039_bib0050","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/cmdc.201000087","article-title":"A structure-activity relationship study of the antimalarial and antileishmanial activities of nonpeptide macrocyclic histone deacetylase inhibitors","volume":"5","author":"Guerrant","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2018.11.039_bib0055","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1021\/jm100507q","article-title":"Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton","volume":"53","author":"Mwakwari","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.039_bib0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bmc.2009.10.042","article-title":"Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group","volume":"18","author":"Patil","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.039_bib0065","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1021\/acs.jmedchem.5b00539","article-title":"Dual-mode HDAC prodrug for covalent modification and subsequent inhibitor release","volume":"58","author":"Daniel","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.039_bib0070","doi-asserted-by":"crossref","first-page":"9974","DOI":"10.1021\/acs.jmedchem.6b01426","article-title":"Efficient palladium-triggered release of vorinostat from a bioorthogonal precursor","volume":"59","author":"Rubio-Ruiz","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.039_bib0075","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1128\/AAC.48.4.1435-1436.2004","article-title":"Antimalarial and antileishmanial activities of aroyl-pyrrolyl-Hydroxyamides, a new class of histone deacetylase inhibitors","volume":"48","author":"Mai","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2018.11.039_bib0080","series-title":"Compounds for the Treatment of Diseases Caused by Parasites of the Genus Leishmania, ES2608476 (B1)","author":"Gomez Vidal","year":"2017"},{"key":"10.1016\/j.phrs.2018.11.039_bib0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1039\/df9511100055","article-title":"A study of the nucleation and growth processes in the synthesis of colloidal gold","volume":"11","author":"Turkevich","year":"1951","journal-title":"Discuss. Faraday Soc."},{"key":"10.1016\/j.phrs.2018.11.039_bib0090","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/IAI.71.3.1225-1233.2003","article-title":"Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages","volume":"71","author":"Zamboni","year":"2003","journal-title":"Infect. Immun."},{"key":"10.1016\/j.phrs.2018.11.039_bib0095","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1021\/np5008697","article-title":"(\u2212)-\u03b1-Bisabolol, a promising oral compound for the treatment of visceral leishmaniasis","volume":"78","author":"Corpas-L\u00f3pez","year":"2015","journal-title":"J. Nat. Prod."},{"issue":"4","key":"10.1016\/j.phrs.2018.11.039_bib0100","first-page":"283","article-title":"The analysis of fluctuation tests","volume":"74","author":"Gilbert","year":"1980","journal-title":"Mutat. Res. Mutagen. Relat. Sub."},{"key":"10.1016\/j.phrs.2018.11.039_bib0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vetpar.2016.04.001","article-title":"Hair parasite load as a new biomarker for monitoring treatment response in canine leishmaniasis","volume":"223","author":"Corpas-L\u00f3pez","year":"2016","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.phrs.2018.11.039_bib0110","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.2174\/092986712800229023","article-title":"The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases - part I","volume":"19","author":"Schmidt","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.039_bib0115","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S003118201300142X","article-title":"Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections","volume":"141","author":"Don","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.phrs.2018.11.039_bib0120","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1186\/1471-2164-15-849","article-title":"Stage-specific differential gene expression in Leishmania infantum: from the foregut of Phlebotomus perniciosus to the human phagocyte","volume":"15","author":"Alcolea","year":"2014","journal-title":"BMC Genomics"},{"key":"10.1016\/j.phrs.2018.11.039_bib0125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.gene.2005.06.047","article-title":"Targeted disruption of cytosolic SIR2 deacetylase discloses its essential role in Leishmania survival and proliferation","volume":"363","author":"Vergnes","year":"2005","journal-title":"Gene"},{"key":"10.1016\/j.phrs.2018.11.039_bib0130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijpddr.2016.12.005","article-title":"Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth","volume":"7","author":"Chua","year":"2017","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.phrs.2018.11.039_bib0135","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Haggarty","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.11.039_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpddr.2018.01.002","article-title":"Synthesis of aminophenylhydroxamate and aminobenzylhydroxamate derivatives and in vitro screening for antiparasitic and histone deacetylase inhibitory activity","author":"Loeuillet","year":"2018","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.phrs.2018.11.039_bib0145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jmgm.2015.10.006","article-title":"Homology modeling of parasite histone deacetylases to guide the structure-based design of selective inhibitors","volume":"62","author":"Melesina","year":"2015","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.phrs.2018.11.039_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.phrs.2018.11.039_bib0155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.exppara.2013.07.008","article-title":"Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL\/6 mice","volume":"135","author":"de Carvalho","year":"2013","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.phrs.2018.11.039_bib0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ejpb.2010.11.010","article-title":"Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages","volume":"77","author":"Arnida","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.phrs.2018.11.039_bib0165","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.2174\/138161281941131219135458","article-title":"Nanotechnological strategies for the treatment of neglected diseases","volume":"19","author":"Khalil","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2018.11.039_bib0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.colsurfb.2013.01.061","article-title":"One pot synthesis of gold nanoparticles and application in chemotherapy of wild and resistant type visceral leishmaniasis","volume":"107","author":"Das","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.phrs.2018.11.039_bib0175","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.colsurfb.2009.03.004","article-title":"Effect of surface charge of magnetite nanoparticles on their internalization into breast cancer and umbilical vein endothelial cells","volume":"71","author":"Osaka","year":"2009","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.phrs.2018.11.039_bib0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/10611869409015905","article-title":"Control of in vivo fate of albumin derivatives utilizing combined chemical modification","volume":"2","author":"Fujita","year":"1994","journal-title":"J. Drug Target"},{"key":"10.1016\/j.phrs.2018.11.039_bib0185","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0304-8853(93)91115-N","article-title":"Colloidal magnetic resonance contrast agents: effect of particle surface on biodistribution","volume":"122","author":"Papisov","year":"1993","journal-title":"J. Magn. Magn. Mater."},{"key":"10.1016\/j.phrs.2018.11.039_bib0190","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1021\/bc049951i","article-title":"Toxicity of gold nanoparticles functionalized with cationic and anionic side chains","volume":"15","author":"Goodman","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.phrs.2018.11.039_bib0195","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic prediction of oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.phrs.2018.11.039_bib0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006422","article-title":"Infection-adapted emergency hematopoiesis promotes visceral leishmaniasis","volume":"13","author":"Abidin","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.phrs.2018.11.039_bib0205","series-title":"Ser. Inf. T\u00e9cnicos.","first-page":"949","author":"Control de la leishmaniasis","year":"2010"},{"key":"10.1016\/j.phrs.2018.11.039_bib0210","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1111\/bph.13942","article-title":"Correlation between human ether-a-go-go-related gene channel inhibition and action potential prolongation","volume":"174","author":"Saxena","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2018.11.039_bib0215","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0165-1161(75)90046-1","article-title":"Methods for detecting carcinogens and mutagens with the Salmonella\/mammalian-microsome mutagenicity test","volume":"31","author":"Ames","year":"1975","journal-title":"Mutat. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818311265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818311265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T10:34:16Z","timestamp":1554460456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818311265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":43,"alternative-id":["S1043661818311265"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.11.039","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A nanodelivered Vorinostat derivative is a promising oral compound for the treatment of visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.11.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}